

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM307220

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	CHANGE OF NAME		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Envivo Pharmaceuticals, Inc.		04/02/2014	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Forum Pharmaceuticals Inc.		
<b>Street Address:</b>	500 Arsenal Street		
<b>City:</b>	Watertown		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	02742		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 9</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	76715546	FORUM PHARMACEUTICALS	
<b>Serial Number:</b>	86174471	FORUM PHARMACEUTICALS	
<b>Serial Number:</b>	86174446		
<b>Serial Number:</b>	86174459	FORUM PHARMACEUTICALS	
<b>Serial Number:</b>	86234297	LUMEMRY	
<b>Serial Number:</b>	86234346	LUMEMRI	
<b>Serial Number:</b>	86234381	LUMORY	
<b>Serial Number:</b>	86234482	LUMORRY	
<b>Serial Number:</b>	86266220	FEARLESS FOCUS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2024084400		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2024084000		
<b>Email:</b>	docketing@finnegan.com		
<b>Correspondent Name:</b>	Julia A. Matheson		
<b>Address Line 1:</b>	901 New York Avenue, N.W.		
<b>Address Line 4:</b>	Washington, D.C. 20001		
<b>ATTORNEY DOCKET NUMBER:</b>	12438.0999-00000		
<b>NAME OF SUBMITTER:</b>	Julia A. Matheson		

OP \$240.00 76715546

<b>SIGNATURE:</b>	/Julia A. Matheson/
<b>DATE SIGNED:</b>	06/10/2014
<b>Total Attachments: 4</b> source=EnVivo 4_2_2014#page1.tif source=EnVivo 4_2_2014#page2.tif source=EnVivo 4_2_2014#page3.tif source=EnVivo 4_2_2014#page4.tif	

# Delaware

PAGE 1

*The First State*

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "ENVIVO PHARMACEUTICALS, INC.", CHANGING ITS NAME FROM "ENVIVO PHARMACEUTICALS, INC." TO "FORUM PHARMACEUTICALS INC.", FILED IN THIS OFFICE ON THE SECOND DAY OF APRIL, A.D. 2014, AT 10:01 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

3393710 8100

140416690



  
Jeffrey W. Bullock, Secretary of State  
AUTHENTICATION: 1260101

DATE: 04-02-14

You may verify this certificate online  
at [corp.delaware.gov/authver.shtml](http://corp.delaware.gov/authver.shtml)

TRADEMARK  
REEL: 005300 FRAME: 0064

CERTIFICATE OF AMENDMENT  
OF  
CERTIFICATE OF INCORPORATION  
OF  
ENVIVO PHARMACEUTICALS, INC.

EnVivo Pharmaceuticals, Inc. (the "Corporation"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "DGCL"), does hereby certify:

The Board of Directors of the Corporation, by resolution duly adopted in accordance with Sections 141 and 242 of the DGCL, approved an amendment to the Fourth Amended and Restated Certificate of Incorporation of the Corporation, as amended to date, and declared said amendment to be advisable. The stockholders of the Corporation duly approved said amendment by written consent in accordance with Sections 228 and 242 of the DGCL. The resolution provides that the Fourth Amended and Restated Certificate of Incorporation filed on June 10, 2008, as amended by Certificates of Amendment filed on March 18, 2010, March 18, 2011, November 14, 2012, July 15, 2013, and November 14, 2013, is further amended as follows:

1. Striking out Article First and replacing it with the following:

"FIRST: The name of the corporation is Forum Pharmaceuticals Inc. (the "Corporation")."

2. Striking out the first paragraph of Article Fifth and substituting the following new paragraph in lieu thereof:

"FIFTH. Giving effect to the stock combination set forth in Article Fourth above, the total number of shares of capital stock of all classes that the Corporation shall have authority to issue is 258,370,000 shares of Common Stock, \$0.001 par value (the "Common Stock")."

3. Striking out the second paragraph of Article Fifth and substituting the following new paragraph in lieu thereof:

“The 258,370,000 shares of Common Stock the Corporation shall have the authority to issue shall consist of:

(i) 221,400,000 shares of Class A Voting Common Stock, \$0.001 par value (the “Class A Voting Common Stock”); and

(ii) 36,970,000 shares of Class B Non-Voting Common Stock, \$0.001 par value (the “Class B Non-Voting Common Stock”).”

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its duly authorized officer this 2nd day of April 2014.

ENVIVO PHARMACEUTICALS, INC.

By: /s/ Deborah Dunsire  
Deborah Dunsire, M.D., President